Inovio Pharmaceuticals Inc (INO)
4.30
-0.47
(-9.85%)
USD |
NASDAQ |
Nov 15, 12:44
Inovio Pharmaceuticals Free Cash Flow (Quarterly): -28.66M for June 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -28.66M |
| March 31, 2024 | -28.80M |
| December 31, 2023 | -26.28M |
| September 30, 2023 | -29.11M |
| June 30, 2023 | -32.34M |
| March 31, 2023 | -36.96M |
| December 31, 2022 | -36.51M |
| September 30, 2022 | -67.55M |
| June 30, 2022 | -51.25M |
| March 31, 2022 | -61.88M |
| December 31, 2021 | -38.53M |
| September 30, 2021 | -46.66M |
| June 30, 2021 | -78.67M |
| March 31, 2021 | -53.08M |
| December 31, 2020 | -52.18M |
| September 30, 2020 | -74.54M |
| June 30, 2020 | -27.19M |
| March 31, 2020 | -25.59M |
| December 31, 2019 | -13.85M |
| September 30, 2019 | -27.87M |
| June 30, 2019 | -24.01M |
| March 31, 2019 | -33.11M |
| December 31, 2018 | -17.62M |
| September 30, 2018 | -24.80M |
| June 30, 2018 | -19.48M |
| Date | Value |
|---|---|
| March 31, 2018 | -13.73M |
| December 31, 2017 | -14.83M |
| September 30, 2017 | -20.90M |
| June 30, 2017 | -21.76M |
| March 31, 2017 | -16.02M |
| December 31, 2016 | -14.97M |
| September 30, 2016 | -19.12M |
| June 30, 2016 | -15.99M |
| March 31, 2016 | -16.42M |
| December 31, 2015 | -7.600M |
| September 30, 2015 | 14.64M |
| June 30, 2015 | -9.668M |
| March 31, 2015 | -12.60M |
| December 31, 2014 | -8.247M |
| September 30, 2014 | -8.364M |
| June 30, 2014 | -8.854M |
| March 31, 2014 | -5.739M |
| December 31, 2013 | 0.9486M |
| September 30, 2013 | -5.889M |
| June 30, 2013 | -5.448M |
| March 31, 2013 | -5.170M |
| December 31, 2012 | -5.543M |
| September 30, 2012 | -6.050M |
| June 30, 2012 | -5.420M |
| March 31, 2012 | -5.534M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-78.67M
Minimum
Jun 2021
-13.85M
Maximum
Dec 2019
-42.61M
Average
-36.96M
Median
Mar 2023
Free Cash Flow (Quarterly) Benchmarks
| Baxter International Inc | 229.00M |
| Novavax Inc | 311.14M |
| AIM ImmunoTech Inc | -3.237M |
| Protalix BioTherapeutics Inc | -3.782M |
| Armata Pharmaceuticals Inc | -11.54M |